Blood test for bowel cancer uses spectral fingerprint to help reduce unnecessary colonoscopies

A new blood test developed in Wales harnesses the power of AI to detect the early signs of bowel cancer.

CanSense, a Swansea University spin-out, has spent seven years developing an affordable and accessible cancer test that can be performed at local GPs to avoid delayed detection.

Test results are shared within 48 hours, allowing GPs to make immediate decisions for their patients, enabling a quicker pathway to treatment.

“COVID-19 has highlighted the necessity for accurate and affordable testing to relieve the pressure on traditional diagnostic services within the NHS, to ensure those with bowel cancer receive the treatment they need right away,” the developers say.

“It is hoped that additional funding will accelerate mainstream primary care adoption of the proven technology to help decrease the backlog of patients waiting for referrals.”

See the full report on page 19 of the May 2021 issue of RAD Magazine.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more